期刊
CELL
卷 184, 期 19, 页码 5015-+出版社
CELL PRESS
DOI: 10.1016/j.cell.2021.07.029
关键词
-
资金
- JRI
- Rosanne H. Silbermann Foundation
- Sanders Family
- Weill Cornell Medicine Division of Pediatric Gastroenterology and Nutrition
- NIH [R01AI143842, R01AI123368, R01AI145989, U01AI095608, R21CA249274, R01AI162936, F32AI124517, K01DK103952, R01DK124617]
- Burroughs Wellcome Fund
- Wade F.B. Thompson/Cancer Research Institute (CRI) CLIP Investigator grant
- Meyer Cancer Center Collaborative Research Initiative
- Dalton Family Foundation
- Crohn's and Colitis Foundation [519428]
- Philippe Foundation
- Jill Roberts Center for IBD
- Cure for IBD
Research shows that ILC3s play a protective role in cancer, and alterations in CRC may lead to dysfunctional adaptive immunity, tumor progression, and immunotherapy resistance.
Group 3 innate lymphoid cells (ILC3s) regulate immunity and inflammation, yet their role in cancer remains elusive. Here, we identify that colorectal cancer (CRC) manifests with altered ILC3s that are characterized by reduced frequencies, increased plasticity, and an imbalance with T cells. We evaluated the consequences of these changes in mice and determined that a dialog between ILC3s and T cells via major histocompatibility complex class II (MHCII) is necessary to support colonization with microbiota that subsequently induce type1 immunity in the intestine and tumor microenvironment. As a result, mice lacking ILC3-specific MHCII develop invasive CRC and resistance to anti-PD-1 immunotherapy. Finally, humans with dysregulated intestinal ILC3s harbor microbiota that fail to induce type-1 immunity and immunotherapy responsiveness when transferred to mice. Collectively, these data define a protective role for ILC3s in cancer and indicate that their inherent disruption in CRC drives dysfunctional adaptive immunity, tumor progression, and immunotherapy resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据